The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial

Overview

Journal J Atheroscler Thromb

Date 2020 Mar 3

PMID 32115470

Citations 25

Authors

Takao Sato

Yoshifusa Aizawa

Sho Yuasa

Satoshi Fujita

Yoshio Ikeda

Masaaki Okabe

Affiliations

Soon will be listed here.

Abstract

Aim: Epicardial adipose tissue (EAT) may be associated with arrhythmogenesis. P-wave indices such as P-wave dispersion and P-wave variation indicated a slowed conduction velocity within the atria. This study investigated the effect of dapagliflozin on EAT volume and P-wave indices.

Methods: In the present ad hoc analysis, 35 patients with type 2 diabetes mellitus and coronary artery disease were classified into dapagliflozin group (n=18) and conventional treatment group (n=17). At baseline, EAT volume, HbA1c and plasma level of tumor necrotic factor-α (TNF-α) levels, echocardiography, and 12-lead electrocardiogram (ECG) were performed. EAT volume was measured using computed tomography. Using 12-lead ECG, P-wave indices were measured.

Results: At baseline, EAT volumes in the dapagliflozin and conventional treatment groups were 113±20 and 110±27 cm, respectively. Not only HbA1c and plasma level of TNF-α but also echocardiography findings including left atrial dimension and P-wave indices were comparable between the two groups. After 6 months, plasma level of TNF-α as well as EAT volume significantly decreased in the dapagliflozin group only. P-wave dispersion and P-wave variation significantly decreased in the dapagliflozin group only (-9.2±8.7 vs. 5.9±19.9 ms, p=0.01; -3.5±3.5 vs. 1.7±5.9 ms, p=0.01). The change in P-wave dispersion correlated with changes in EAT volume and plasma level of TNF-α. In multivariate analysis, the change in EAT volume was an independent determinant of the change in P-wave dispersion.

Conclusion: Dapagliflozin reduced plasma level of TNF-α, EAT volume, and P-wave indices, such as P-wave dispersion. The changes in P-wave indices were especially associated with changes in EAT volume.The number and date of registration: UMIN000035660, 24/Jan/2019.

Citing Articles

Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias.

Bahrami P, Aromolaran K, Aromolaran A J Cell Physiol. 2025; 240(2):e70012.

PMID: 39943721 PMC: 11822244. DOI: 10.1002/jcp.70012.

Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post-Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Abdelhadi N, Ragab K, Elkholy M, Koneru J, Ellenbogen K, Pillai A J Cardiovasc Electrophysiol. 2025; 36(3):673-682.

PMID: 39789826 PMC: 11903381. DOI: 10.1111/jce.16544.

SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.

Morciano C, Gugliandolo S, Capece U, Giuseppe G, Mezza T, Ciccarelli G Cardiovasc Diabetol. 2024; 23(1):449.

PMID: 39702365 PMC: 11660748. DOI: 10.1186/s12933-024-02539-x.

An enhanced deep learning method for the quantification of epicardial adipose tissue.

Tang K, Liao X, Yuan L, He S, Wang M, Mei X Sci Rep. 2024; 14(1):24947.

PMID: 39438553 PMC: 11496533. DOI: 10.1038/s41598-024-75659-9.

Potential Mechanisms of Epicardial Adipose Tissue Influencing Heart Failure with Preserved Ejection Fraction.

Li Q, Muhib U, Ma X, Liu Z, Gao F, Wang Z Rev Cardiovasc Med. 2024; 25(9):311.

PMID: 39355598 PMC: 11440401. DOI: 10.31083/j.rcm2509311.

References

Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S . The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018; 17(1):6. PMC: 5753537. DOI: 10.1186/s12933-017-0658-8. View

Bell D, Goncalves E . Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2018; 21(2):210-217. DOI: 10.1111/dom.13512. View

Lumeng C, Bodzin J, Saltiel A . Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007; 117(1):175-84. PMC: 1716210. DOI: 10.1172/JCI29881. View

Yagi S, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D . Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017; 9:78. PMC: 5628447. DOI: 10.1186/s13098-017-0275-4. View

Wong C, Ganesan A, Selvanayagam J . Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2016; 38(17):1294-1302. DOI: 10.1093/eurheartj/ehw045. View

Pathak R, Middeldorp M, Lau D, Mehta A, Mahajan R, Twomey D . Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64(21):2222-31. DOI: 10.1016/j.jacc.2014.09.028. View

Abel E, OShea K, Ramasamy R . Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012; 32(9):2068-76. PMC: 3646067. DOI: 10.1161/ATVBAHA.111.241984. View

Falchi A, Grecchi I, Muggia C, Tinelli C . Weight loss and P wave dispersion: a preliminary study. Obes Res Clin Pract. 2014; 8(6):e614-7. DOI: 10.1016/j.orcp.2014.08.005. View

Iacobellis G, Barbaro G . Epicardial adipose tissue feeding and overfeeding the heart. Nutrition. 2018; 59:1-6. DOI: 10.1016/j.nut.2018.07.002. View

10.

Magnani J, Mazzini M, Sullivan L, Williamson M, Ellinor P, Benjamin E . P-wave indices, distribution and quality control assessment (from the Framingham Heart Study). Ann Noninvasive Electrocardiol. 2010; 15(1):77-84. PMC: 2901840. DOI: 10.1111/j.1542-474X.2009.00343.x. View

11.

Baker A, da Silva N, Quinn D, Harte A, Pagano D, Bonser R . Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006; 5:1. PMC: 1352345. DOI: 10.1186/1475-2840-5-1. View

12.

Sato T, Kameyama T, Ohori T, Matsuki A, Inoue H . Effects of eicosapentaenoic acid treatment on epicardial and abdominal visceral adipose tissue volumes in patients with coronary artery disease. J Atheroscler Thromb. 2014; 21(10):1031-43. DOI: 10.5551/jat.23390. View

13.

Sacks H, Fain J . Human epicardial adipose tissue: a review. Am Heart J. 2007; 153(6):907-17. DOI: 10.1016/j.ahj.2007.03.019. View

14.

Tosaki T, Kamiya H, Himeno T, Kato Y, Kondo M, Toyota K . Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes. Intern Med. 2017; 56(6):597-604. PMC: 5410466. DOI: 10.2169/internalmedicine.56.7196. View

15.

Camsari A, Pekdemir H, Akkus M, Yenihan S, Doven O, Cin V . Long-term effects of beta blocker therapy on P-wave duration and dispersion in congestive heart failure patients: a new effect?. J Electrocardiol. 2003; 36(2):111-6. DOI: 10.1054/jelc.2003.50020. View

16.

Chung M, Martin D, Sprecher D, Wazni O, Kanderian A, Carnes C . C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104(24):2886-91. DOI: 10.1161/hc4901.101760. View

17.

Hirata Y, Tabata M, Kurobe H, Motoki T, Akaike M, Nishio C . Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol. 2011; 58(3):248-55. DOI: 10.1016/j.jacc.2011.01.048. View

18.

Birkeland K, Jorgensen M, Carstensen B, Persson F, Gulseth H, Thuresson M . Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017; 5(9):709-717. DOI: 10.1016/S2213-8587(17)30258-9. View

19.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

20.

Calle E, Thun M, Petrelli J, Rodriguez C, Heath Jr C . Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341(15):1097-105. DOI: 10.1056/NEJM199910073411501. View